Ghazanfar et al
The gastrointestinal side effects of GLP-1 agentsparticularly vomiting and diarrheacan lead to depletion of essential electrolytes including sodium, magnesium, potassium, and calcium, all of which are critical for normal muscle contraction and relaxation
3 Introduction/background: a novel dual incretin analog Despite historical research stating GIP did not assist in lowering blood glucose even with supratherapeutic levels, the success of GLP-1 RAs has led to the approval of a novel GLP-1/GIP RA, tirzepatide [42]
Safety depends on the exact ingredients, product quality, and the person's health conditions
For the first time in medical history, we have medications that address weight management at the hormonal and neurological levelthe same way we treat diabetes, hypertension, and other chronic conditions
Repurposing of long-acting FDA-approved GLP-1 receptor agonists such as semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple-agonist retatrutide which additionally targets glucagon receptors and is currently in clinical trials for obesity, may offer a promising strategy treating AUD
